Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug Vedotin and Pucotenlimab as Neoadjuvant Therapy in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma
NCT07545083Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Apr 2026
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
Phase 2, open-label, single-arm trial of becotatug vedotin and pucotenlimab in oral squamous cell carcinoma (OSCC) and oropharyngeal squamous cell carcinoma (OPSCC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Major Pathological Response at 2 months. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
becotatug vedotinpucotenlimab
03
Conditions
oral squamous cell carcinoma (OSCC)oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT07545083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07545083.